163 related articles for article (PubMed ID: 24778079)
1. Lack of association between KRAS mutations and 18F-FDG PET/CT in Caucasian metastatic colorectal cancer patients.
Krikelis D; Skoura E; Kotoula V; Rondogianni P; Pianou N; Samartzis A; Xanthakis I; Fountzilas G; Datseris IE
Anticancer Res; 2014 May; 34(5):2571-9. PubMed ID: 24778079
[TBL] [Abstract][Full Text] [Related]
2. Relationship Between 18F-FDG PET/CT Scans and KRAS Mutations in Metastatic Colorectal Cancer.
Kawada K; Toda K; Nakamoto Y; Iwamoto M; Hatano E; Chen F; Hasegawa S; Togashi K; Date H; Uemoto S; Sakai Y
J Nucl Med; 2015 Sep; 56(9):1322-7. PubMed ID: 26135109
[TBL] [Abstract][Full Text] [Related]
3. Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS.
Iwamoto M; Kawada K; Nakamoto Y; Itatani Y; Inamoto S; Toda K; Kimura H; Sasazuki T; Shirasawa S; Okuyama H; Inoue M; Hasegawa S; Togashi K; Sakai Y
J Nucl Med; 2014 Dec; 55(12):2038-44. PubMed ID: 25453050
[TBL] [Abstract][Full Text] [Related]
4. Multifunctional imaging signature for V-KI-RAS2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in colorectal cancer.
Miles KA; Ganeshan B; Rodriguez-Justo M; Goh VJ; Ziauddin Z; Engledow A; Meagher M; Endozo R; Taylor SA; Halligan S; Ell PJ; Groves AM
J Nucl Med; 2014 Mar; 55(3):386-91. PubMed ID: 24516257
[TBL] [Abstract][Full Text] [Related]
5. Relationship between 18F-fluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer.
Kawada K; Nakamoto Y; Kawada M; Hida K; Matsumoto T; Murakami T; Hasegawa S; Togashi K; Sakai Y
Clin Cancer Res; 2012 Mar; 18(6):1696-703. PubMed ID: 22282467
[TBL] [Abstract][Full Text] [Related]
6. Correlation between PET/CT parameters and KRAS expression in colorectal cancer.
Chen SW; Chiang HC; Chen WT; Hsieh TC; Yen KY; Chiang SF; Kao CH
Clin Nucl Med; 2014 Aug; 39(8):685-9. PubMed ID: 24978328
[TBL] [Abstract][Full Text] [Related]
7. Relationship between KRAS mutations and dual time point
Mao W; Zhou J; Zhang H; Qiu L; Tan H; Hu Y; Shi H
Abdom Radiol (NY); 2019 Jun; 44(6):2059-2066. PubMed ID: 30143816
[TBL] [Abstract][Full Text] [Related]
8. Relationship Between 18F-Fluorodeoxyglucose Uptake and V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation in Colorectal Cancer Patients: Variability Depending on C-Reactive Protein Level.
Lee JH; Kang J; Baik SH; Lee KY; Lim BJ; Jeon TJ; Ryu YH; Sohn SK
Medicine (Baltimore); 2016 Jan; 95(1):e2236. PubMed ID: 26735530
[TBL] [Abstract][Full Text] [Related]
9. Genetic Alterations in Colorectal Cancer Have Different Patterns on 18F-FDG PET/CT.
Chen SW; Lin CY; Ho CM; Chang YS; Yang SF; Kao CH; Chang JG
Clin Nucl Med; 2015 Aug; 40(8):621-6. PubMed ID: 26018692
[TBL] [Abstract][Full Text] [Related]
10. Correlation between KRAS mutation and
Cho A; Jo K; Hwang SH; Lee N; Jung M; Yun M; Hwang HS
Abdom Radiol (NY); 2017 Jun; 42(6):1621-1626. PubMed ID: 28161825
[TBL] [Abstract][Full Text] [Related]
11. The value of
Oner AO; Budak ES; Yıldırım S; Aydın F; Sezer C
Hell J Nucl Med; 2017; 20(2):160-165. PubMed ID: 28697193
[TBL] [Abstract][Full Text] [Related]
12. Correlation between
Liu X; Wang SC; Ni M; Xie Q; Zhang YF; Lv WF; Geng GY
Abdom Radiol (NY); 2022 Apr; 47(4):1255-1264. PubMed ID: 35138462
[TBL] [Abstract][Full Text] [Related]
13. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
Caicedo C; Garcia-Velloso MJ; Lozano MD; Labiano T; Vigil Diaz C; Lopez-Picazo JM; Gurpide A; Zulueta JJ; Richter Echevarria JA; Perez Gracia JL
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic performance of F-18 FDG PET/CT for prediction of KRAS mutation in colorectal cancer patients: a systematic review and meta-analysis.
Kim SJ; Pak K; Kim K
Abdom Radiol (NY); 2019 May; 44(5):1703-1711. PubMed ID: 30603881
[TBL] [Abstract][Full Text] [Related]
15. CT texture analysis for the prediction of KRAS mutation status in colorectal cancer via a machine learning approach.
Taguchi N; Oda S; Yokota Y; Yamamura S; Imuta M; Tsuchigame T; Nagayama Y; Kidoh M; Nakaura T; Shiraishi S; Funama Y; Shinriki S; Miyamoto Y; Baba H; Yamashita Y
Eur J Radiol; 2019 Sep; 118():38-43. PubMed ID: 31439256
[TBL] [Abstract][Full Text] [Related]
16. Correlations among KRAS Mutation, Microsatellite Instability, and 18F-FDG Uptake in Colon Cancer.
Lee SS; Choi SJ; Park JS
Asian Pac J Cancer Prev; 2022 Oct; 23(10):3501-3506. PubMed ID: 36308376
[TBL] [Abstract][Full Text] [Related]
17. First-in-Humans PET Imaging of
Li X; Ye J; Wang J; Quan Z; Li G; Ma W; Zhang M; Yang W; Wang J; Ma T; Kang F; Wang J
J Nucl Med; 2023 Dec; 64(12):1880-1888. PubMed ID: 37827842
[TBL] [Abstract][Full Text] [Related]
18. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.
Ozkan E; Soydal C; Araz M; Kir KM; Ibis E
Nucl Med Commun; 2012 Apr; 33(4):395-402. PubMed ID: 22367859
[TBL] [Abstract][Full Text] [Related]
19. (18)F-FDG PET/CT imaging in rectal cancer: relationship with the RAS mutational status.
Lovinfosse P; Koopmansch B; Lambert F; Jodogne S; Kustermans G; Hatt M; Visvikis D; Seidel L; Polus M; Albert A; Delvenne P; Hustinx R
Br J Radiol; 2016 Jul; 89(1063):20160212. PubMed ID: 27146067
[TBL] [Abstract][Full Text] [Related]
20. CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Skougaard K; Johannesen HH; Nielsen D; Schou JV; Jensen BV; Høgdall EV; Hendel HW
Cancer Med; 2014 Oct; 3(5):1294-301. PubMed ID: 24941936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
